Ettinger David S
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.
Clin Lung Cancer. 2002 Mar;3 Suppl 1:S22-5.
Pemetrexed (Alimta) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B12 and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.
培美曲塞（力比泰）是一种新型的多靶点抗叶酸药物，对非小细胞肺癌（NSCLC）具有活性。作为单一药物，缓解率为16%-23%。作为二线治疗，在先前接受过顺铂或非铂类化疗的NSCLC患者中，培美曲塞的缓解率分别为5%和14%。培美曲塞联合顺铂的缓解率为38.9%-44.8%，中位生存期为8.9-10.9个月。培美曲塞加吉西他滨治疗NSCLC的缓解率低于25%。与培美曲塞相关的主要毒性是中性粒细胞减少，补充维生素B12和叶酸营养剂可能会降低这种毒性。治疗NSCLC患者需要对培美曲塞与其他药物联合进行更多研究。
